Hossein Borghaei, DO, MS; and Martin Reck, MD, PhD, discuss factors that affect treatment selection in NSCLC, and the role of molecular and biomarker testing.
Back
Immune Checkpoint Inhibitors in First-line Treatment of Metastatic NSCLC
Hossein Borghaei, DO, MS, and Martin Reck, MD, PhD, highlight recent advances and use of immune checkpoint inhibitors in the treatment of first-line metastatic non-small cell lung cancer.
Immune Checkpoint Inhibitors in First-line Treatment of Metastatic NSCLC
Episodes
All
All
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Iberdomide Plus Daratumumab/Dexamethasone for R/R Myeloma
2
Dive into the Data Supporting the FDA Approval of Iberdomide Plus Daratumumab/Dexamethasone in R/R Myeloma
3
Five Under 5: Top Oncology Videos for the Week of 8/9
4
Zipalertinib Plus Chemotherapy Improves PFS in First-Line EGFR Exon 20 Insertion+ NSCLC
5